drugset / Trial / NCT03179475
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
Phase 4
Completed
1 enrolled
University of British Columbia
International Collaboration on Repair Discoveries · collabPurdue Pharma, Canada · collabVancouver Coastal Health · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will be investigating the effectiveness of oxycodone-naloxone (brand name Targin®) at treating chronic pain in individuals with spinal cord injury. The goal of the study is to compare the effectiveness of Targin® at treating chronic pain in individuals with sub-acute and chronic spinal cord injury compared to opioid medication that is not compounded with naloxone.
Timeline
- Start
- 2019-09-05
- Primary completion
- 2021-11-29
- Completion
- 2021-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naloxone | Small molecule | 2.5 mg | Oral |
| Subject | Naloxone | Small molecule | 5 mg | Oral |
| Subject | Naloxone | Small molecule | 10 mg | Oral |
| Subject | Naloxone | Small molecule | 20 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 5 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 10 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 20 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 40 mg | Oral |